- Home
- ADPT vs CINT Comparison
ADPT vs CINT Comparison
Compare ADPT & CINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- CINT
- Stock Information
- Founded
- ADPT 2009
- CINT 1995
- Country
- ADPT United States
- CINT Brazil
- Employees
- ADPT N/A
- CINT N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- CINT EDP Services
- Sector
- ADPT Health Care
- CINT Technology
- Exchange
- ADPT Nasdaq
- CINT Nasdaq
- Market Cap
- ADPT 929.8M
- CINT 836.5M
- IPO Year
- ADPT 2019
- CINT 2021
- Fundamental
- Price
- ADPT $6.81
- CINT $6.37
- Analyst Decision
- ADPT Buy
- CINT Buy
- Analyst Count
- ADPT 4
- CINT 6
- Target Price
- ADPT $6.75
- CINT $7.72
- AVG Volume (30 Days)
- ADPT 1.3M
- CINT 57.6K
- Earning Date
- ADPT 02-12-2025
- CINT 03-06-2025
- Dividend Yield
- ADPT N/A
- CINT N/A
- EPS Growth
- ADPT N/A
- CINT 15.05
- EPS
- ADPT N/A
- CINT 0.16
- Revenue
- ADPT $177,282,000.00
- CINT $410,247,558.00
- Revenue This Year
- ADPT $6.48
- CINT $9.20
- Revenue Next Year
- ADPT $18.72
- CINT $14.97
- P/E Ratio
- ADPT N/A
- CINT $39.12
- Revenue Growth
- ADPT N/A
- CINT N/A
- 52 Week Low
- ADPT $2.28
- CINT $3.34
- 52 Week High
- ADPT $7.46
- CINT $8.04
- Technical
- Relative Strength Index (RSI)
- ADPT 54.92
- CINT 53.35
- Support Level
- ADPT $5.98
- CINT $5.60
- Resistance Level
- ADPT $7.28
- CINT $6.50
- Average True Range (ATR)
- ADPT 0.54
- CINT 0.24
- MACD
- ADPT -0.00
- CINT 0.04
- Stochastic Oscillator
- ADPT 58.06
- CINT 85.00
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About CINT CI&T Inc
CI&T Inc is engaged in providing strategy, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.